

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Otis Brawley, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: **July 24, 2007**

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application (NDA) 021,801, proposed trade name Orplatna (satraplatin capsules), originally developed by Johnson Matthey Pharmaceuticals, a subsidiary of Johnson Matthey PLC, with licensing rights to Spectrum Pharmaceuticals. Spectrum Pharmaceuticals licensed the global rights to GPC Biotech AG, proposed indication for the treatment of patients with androgen independent (hormone refractory) prostate cancer (HRPC) that has failed prior chemotherapy, I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued from \$25,001 to \$50,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waivers are not valid.

/s/
Signature of SGE

June 7, 2007
Date